开发针对肺癌、直肠癌、前列腺癌和宫颈癌的年龄与合并症调整的最优放疗利用模型
研究利用新南威尔士州癌症登记数据(2010-2014)及链接的放疗与住院数据,将癌症特异性C3合并症指数纳入肿瘤部位特异性决策树模型,构建年龄与合并症调整的最优放疗利用模型。结果显示,80岁及以上患者中,除宫颈癌外,实际放疗利用率均低于最优利用率。
要点
- 80岁及以上患者中,NSCLC、SCLC、直肠癌、前列腺癌的实际放疗利用率均低于最优模型估计值,宫颈癌实际利用率高于最优值。
- 该模型首次在最优放疗利用估计中纳入合并症指数,采用癌症特异性C3合并症指数评估放疗适宜性。
- 结论指出实际利用率低于最优值的现象需进一步评估原因并寻求解决方案。
核心结论
- 在80岁及以上患者中,即使调整年龄和合并症后,除宫颈癌外,实际放疗利用率仍低于最优放疗利用率;宫颈癌的实际利用率高于最优利用率。
- 作者认为这一现象需要进一步评估和研究其原因及解决方案。
研究设计与样本
- 研究使用新南威尔士州癌症登记数据(2010-2014年)链接放疗数据(2010-2015年)和住院数据(2008-2015年),确定肺癌、直肠癌、前列腺癌和宫颈癌患者数量。
- 从住院诊断数据计算每位患者的癌症特异性C3「all sites」合并症指数以判断放疗适宜性,并将该指数纳入肿瘤部位特异性决策树模型。
- 实际放疗利用率也通过链接数据集计算。
主要发现
- 2010-2014年新南威尔士州诊断非小细胞肺癌14696例、小细胞肺癌1839例、直肠癌5551例、前列腺癌30935例、宫颈癌1216例。
- 诊断时年龄80岁及以上患者比例分别为:非小细胞肺癌25%(3603例)、小细胞肺癌15%(279例)、直肠癌17%(943例)、前列腺癌12%(3745例)、宫颈癌7%(88例)。
- 使用C3指数计算的80岁及以上患者年龄与合并症调整最优放疗利用率分别为:非小细胞肺癌49%、小细胞肺癌49%、直肠癌43%、前列腺癌51%、宫颈癌40%。
- 80岁及以上患者对应的实际放疗利用率分别为:非小细胞肺癌25%、小细胞肺癌32%、直肠癌27%、前列腺癌16%、宫颈癌56%。
关键数值与推荐
- 最优放疗利用率(年龄与合并症调整,80岁及以上):非小细胞肺癌49%、小细胞肺癌49%、直肠癌43%、前列腺癌51%、宫颈癌40%。
- 实际放疗利用率(80岁及以上):非小细胞肺癌25%、小细胞肺癌32%、直肠癌27%、前列腺癌16%、宫颈癌56%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出该现象需要进一步评估和研究其原因及解决方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Optimal radiotherapy utilisation (RTU) modelling estimates the proportion of people with cancer who would benefit from radiotherapy. Assessment of comorbidities is an important component of the assessment of suitability for radiotherapy in addition to chronological age and life expectancy. Comorbidities have not been considered in previous optimal RTU models. We aimed to develop an age- and comorbidity- adjusted optimal RTU model for patients with lung, rectal, prostate, and cervical cancer, and compare them to actual RTU rates, with a particular focus on those aged 80+ years, METHODS: New South Wales (NSW) Cancer Registry data (2010-2014) linked to radiotherapy data (2010-2015) and hospitalisation data (2008-2015) were used to determine the number of patients diagnosed with lung, rectal, prostate and cervical cancer. The Cancer Specific C3 'all sites' comorbidity index was calculated from hospital diagnosis data for each patient to determine suitability for radiotherapy. The index was then incorporated into a tumour site-specific decision tree model. The actual RTU was also calculated using the linked datasets. RESULTS: 14,696 patients were diagnosed with non-small cell lung cancer (NSCLC), 1839 with small cell lung cancer (SCLC), 5551 with rectal cancer, 30,935 with prostate cancer and 1216 with cervical cancer in New South Wales from 2010-2014. The proportion of patients aged 80+ years at cancer diagnosis was 25% (3603 patients), 15% (279 patients), 17% (943 patients), 12% (3745 patients), and 7% (88 patients) respectively. The age- and comorbidity- adjusted optimal RTU rates for patients aged 80+ years using the C3 index were 49% (NSCLC), 49% (SCLC), 43% (rectal), 51% (prostate) and 40% (cervical). The corresponding actual RTU rates for patients aged 80+ years were 25%, 32%, 27%, 16%, and 56%. CONCLUSION: Even after adjusting for age and comorbidities, the actual radiotherapy utilisation rates were lower than optimal radiotherapy utilisation rates in patients aged 80+ years except for patients with cervical cancer. This warrants further assessment and research into reasons and solutions.
引用
- Mackenzie P, Vajdic C, Delaney G, et al. Development of an age- and comorbidity- adjusted optimal radiotherapy utilisation rate for lung, rectal, prostate and cervical cancers. Radiother Oncol. 2023. PMID: 37619661. doi:10.1016/j.radonc.2023.109862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。